Dear fellow bench scientist,
I cannot tell a lie. Dr. Washington is off today. But if you're working hard in the lab, either because your PI or your inner PI (you) requires it, Dr. Washington has a workaround. Sure, your Facebook friends are posting selfies with their President or El Presidente cocktails. But put down the beaker of despair (think of alcohol as just more glassware to wash) and take Dr. Washington's Instant Holiday.
Biologists are passionate about papers. Here we ask an ASCB member to pick two journal articles that were important, either personally or scientifically, and to answer—briefly and informally—three questions: Why did you pick this paper? What's it about? What does it mean to you?
It was either serendipity or the anxiety of an entire generation of graduate students coming to a boil, but last fall something triggered an explosion of science advocacy on the Emory University campus in Atlanta. A grad student "advocacy journal club" has sprung to life with 50 members, ambitious plans for organizing more, and a working alliance with the dean and with Emory's Office of Governmental Affairs.
NIH Director Francis Collins yesterday unveiled an unusual open access alliance of 10 "biopharmaceutical" companies and eight nonprofits to wade through the growing flood of bio data on four diseases—Alzheimer's, Type 2 diabetes, and the autoimmune disorders, rheumatoid arthritis and lupus—to identify therapeutic targets and characterize biomarkers. All data and analyses will be publicly shared. The pharma and nonprofit allies will put up $230 million over five years in hopes of making translational sense of the mass of new imaging, "omic" sequencing, and other data on these four diseases with massive impacts on public health. The new alliance is called the Accelerating Medicines Partnership (AMP).